###### Key questions

What is already known about this subject?
=========================================

-   In an acute heart failure setting, proenkephalin A 119--159 (penKid) has emerged as a promising prognostic marker for predicting worsening renal function with much faster reactivity time then creatinine, while bioactive adrenomedullin (bio-ADM) has been proposed as a potential marker for assessment of residual congestion.

What does this study add?
=========================

-   This study substantiates the scarce knowledge about both bio-ADM and penkid and identifies two novel biomarkers for congestion assessment and kidney function. Congestion assessed by bio-ADM was associated with longer hospital stay and higher risk of rehospitalisation. penkid was associated with worsening renal function and higher risk of both in-hospital and postdischarge mortality.

How might this impact on clinical practice?
===========================================

-   Bio-ADM might help identify subjects with residual congestion, who could benefit from intensified diuretic therapy. penKid, with its fast rise when kidneys are damaged, could help identify patients who do not tolerate the intensified diuretic therapy, faster than creatinine.

Introduction {#s1}
============

The cardiorenal syndrome can generally be defined as a pathophysiological disorder of the heart and kidneys, where acute or chronic dysfunction in one organ may induce acute or chronic dysfunction in the other organ.[@R1] Worsening renal function (WRF) and neurohormonal activation are important contributors to fluid retention and acute decompensation in heart failure. The use of biomarkers might help to differentiate between different phenotypes in acute heart failure (AHF) with different outcomes and optimal treatment strategies. Biomarkers reflecting haemodynamic stress/systolic dysfunction are the B-type natriuretic peptides (BNP/N-terminal proBNP (NT-proBNP)), which are often used to follow the progression of heart failure.[@R2] However, their prognostic value in predicting death in AHF is suboptimal.[@R3] Also, high baseline values of BNP in patients with AHF have not shown any association with clinical signs of congestion,[@R4] and NT-proBNP-guided therapy was recently shown not to significantly improve time to first hospitalisation or cardiovascular mortality.[@R6]

A biomarker reflecting renal status, Cystatin C, has been found to predict clinical outcomes in patients with AHF with greater accuracy than creatinine, estimated glomerular filtration rate (eGFR) and blood urea nitrogen. However, these results derive mostly from patients with apparently preserved renal function and may not be applicable to patients with heart failure with concomitant renal dysfunction.[@R3] Consequently, new biomarkers are called on for an improved cardiorenal risk stratification of patients with AHF.

Bioactive adrenomedullin (bio-ADM) is a vasoactive peptide hormone and a protective factor of vascular integrity.[@R7] A new immunoassay especially developed to measure bio-ADM[@R8] was recently used in a study suggesting bio-ADM as a marker of congestion in AHF.[@R9] Furthermore, bio-ADM has been shown to be associated with adverse events within 30 days after hospitalisation for AHF.[@R10]

Enkephalin peptides exert cardiodepressive effects.[@R11] One of those is proenkephalin A 119--159 (penKid, also described as PENK), freely filtered through the glomerulus.[@R12] In chronic heart failure, higher penKid concentrations were found to be associated with lower GFR and renal blood flow.[@R13] PenKid has also been shown to predict adverse clinical outcomes in acute myocardial infarction[@R14] and AHF.[@R15] Thus, the possibility to adequately assess congestion together with real time renal function could be of significant value in the prediction and prevention of the cardiorenal syndrome and ultimately improving patient care.

In the present study, taking advantage of two separate AHF cohorts from Sweden and Italy, we examined the association between bio-ADM and clinical signs of congestion and the relationship between penKid and WRF. Furthermore, we assessed the possible impact of bio-ADM and penKid related to worsening of prognosis for each biomarker separately.

Methods {#s2}
=======

HARVEST-Malmö {#s2-1}
-------------

The HeArt and bRain failure inVESTigation trial (HARVEST-Malmö)[@R16] is an ongoing study in Malmö, Sweden, with the sole inclusion criteria being admitted to a cardiology or internal medicine ward for treatment of heart failure regardless of the aetiology, duration or severity. Between March 2014 and August 2018, 324 consecutive patients admitted to cardiology or internal medicine wards under the diagnosis of either new onset or worsening chronic congestive heart failure were enrolled. Inability to consent to the study was the only exclusion criteria. For patients with severe cognitive impairment, defined as mini mental test examination score \<13 points, the relatives are instead being informed and asked for permission for the patient's behalf. The study was complied with the Declaration of Helsinki. A written informed consent was obtained from all participants.

GREAT Network Rome {#s2-2}
------------------

Between May 2013 and March 2015, 245 patients that were referred to the emergency department of Sant'Andrea hospital complaining of heart failure symptoms and signs and who received a final diagnosis of new onset or worsening chronic congestive heart failure were enrolled to the GREAT Network Acute Heart Failure Rome Study, with inability to consent to the study as the only exclusion criteria. The study protocol was complied with the Declaration of Helsinki. A written informed consent was obtained from all participants.

Clinical examination {#s2-3}
--------------------

In both cohorts, the examination included a clinical examination, blood sample donations and blood pressure measurements at admission. Diabetes was defined as either self-reported physician diagnosis of type 1 or type 2 diabetes, or use of antidiabetic medication or fasting plasma glucose ≥7 mmol/L. Prior heart failure was defined as either prior hospitalisation for heart failure or a heart failure diagnosis prior to inclusion in the study.

Laboratory assays {#s2-4}
-----------------

All laboratory assays are described in the [online Supplemental Material](#SP1){ref-type="supplementary-material"}.
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Outcomes {#s2-5}
--------

In both cohorts, patients were examined for signs of congestion (dyspnoea, oedema, signs of congestion on X-ray and auscultatory lung rales). Further, a clinical congestion score (CCS) was calculated by summing the individual scores for each sign of congestion. A score from 0 to 4 points was attributed to each patient.

WRF was defined as an increase of plasma creatinine of \>26.5 μmol/L or 0.3 mg/dL or 50% higher than the admission value within 48 hours of admission.[@R15] In-hospital mortality was defined as all-cause mortality during the hospital stay in both cohorts. For HARVEST-Malmö, where we had follow-up data, 1-year mortality was defined as all-cause mortality within 1 year from study inclusion and obtained from Swedish total population register Statistics Sweden.

Rehospitalisation (available in HARVEST-Malmö only) was defined as the first of any unplanned readmissions for worsening heart failure until 2 July 2018 and was obtained through regional administrative patient registries.

Statistics {#s2-6}
----------

In both cohorts, variables with non-normal distribution (bio-ADM and penKid) were log-transformed and normalised (using z-score transformation) prior to analyses. Since different assays were used for natriuretic peptides, the data from both cohorts were log transformed and then normalised (using z-score transformation) prior to pooling of the natriuretic peptide data. For all analyses, subjects with missing data on any of the covariates were excluded.

The area under the curve (AUC) of bio-ADM for peripheral oedema, in-hospital mortality, 1-year mortality and rehospitalisation was calculated by receiver operating characteristic (ROC) analysis. As for penKid, AUC was calculated for WRF and in-hospital mortality. The cross-sectional associations of bio-ADM with each of the four signs of congestion, as well as bio-ADM with CCS, were explored using logistic regression models.

Correlations between penKid and creatinine on admission were explored using Spearman's correlation test. The cross-sectional associations of penKid and WRF were explored using two logistic regression models: crude (univariable) and in the pooled cohort adjusted for diabetes, systolic blood pressure (SBP), ACE inhibitor (ACEi), angiotensin receptor blockers (ARB), beta-blockers, prior heart failure, creatinine and BNP, all previously associated with WRF (multivariable). The cross-sectional associations of bio-ADM and penKid with in-hospital mortality were explored using univariable and bivariable logistic regression models due to the low event rate (24 events in the pooled cohort).

In HARVEST-Malmö, additional analyses were carried out for 1-year mortality and rehospitalisation at follow-up, using Cox regression models. In analyses of rehospitalisation, subjects that deceased during hospital stay were excluded from the model prior to analysis. Analyses of length of hospital stay were obtained using linear regression models.

Analyses were performed using IBM SPSS Statistics V.25 and a two-sided p\<0.05 was considered statistically significant.

Results {#s3}
=======

Detailed characteristics of the study populations are presented in [table 1](#T1){ref-type="table"}. Number of events for peripheral oedema and WRF within low and high levels of bio-ADM and penKid are presented in the [online supplementary table 1](#SP2){ref-type="supplementary-material"}, where low and high levels are defined based on previous descriptions in literature.[@R8]
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###### 

Baseline characteristics of the HARVEST-Malmö cohort, the GREAT Network Rome cohort and the pooled cohort

                                       HARVEST-Malmö N=322   GREAT Network Rome N=208   Pooled cohort N=530   P value
  ------------------------------------ --------------------- -------------------------- --------------------- ---------
  Demographics                                                                                                
   Age (years)                         75.1±11.1             78.5±9.9                   76.4±10.7             \<0.001
   Female sex (%)                      97 (30.1)             114 (54.8)                 211 (39.8)            \<0.001
   Smoking (%)                         38 (11.8)             29 (13.9)                  67 (12.6)             0.450
  Clinical profile, n (%)                                                                                     
   Systolic blood pressure (mm Hg)     137.3±27.5            150.7±33.7                 142.3±30.8            \<0.001
   Diastolic blood pressure (mm Hg)    73.6±12.6             81.4±16.8                  77.0±14.9             \<0.001
   Ejection fraction (%)               38 (24--52)           40 (27--50)                40 (25--50)           0.036
  Medical history, n (%)                                                                                      
   Diabetes mellitus                   119 (37.0)            75 (36.1)                  194 (36.6)            0.720
   Prior heart failure                 200 (62.1)            85 (40.9)                  285 (53.8)            \<0.001
   Prevalent atrial fibrillation       153 (47.5)            96 (46.2)                  249 (47.0)            0.762
  Medication, n (%)                                                                                           
   ACE inhibitors/ARB                  251 (77.9)            109 (52.4)                 360 (67.9)            \<0.001
   Beta-blockers                       279 (86.6)            101 (48.6)                 380 (71.7)            \<0.001
   Diuretics                           306 (95.0)            132 (63.5)                 438 (82.6)            \<0.001
  Laboratory                                                                                                  
   Bio-ADM (pg/mL)                     39.6 (25.6--64.5)     24.6 (9.5--48.4)           34.6 (18.7--59.3)     \<0.001
   penKid (pmol/L)                     85.3 (62.8--118.4)    109.5 (81.7--168.5)        91.8 (67.9--135.9)    \<0.001
   BNP (pg/mL)                         --                    756 (366--1452)            --                    --
   NT-proBNP (pg/mL)                   4096 (2212--8645)     7811 (2038--10851)         --                    --
   Creatinine (mg/dL) admission        1.32±0.64             1.44±0.91                  1.37±0.76             0.069
   Creatinine (mg/dL) after 48 hours   1.35±0.64             1.53±1.0                   1.42±0.81             0.016
   Potassium (mmol/L)                  3.8±0.5               4.3±0.6                    4.0±0.6               \<0.001
   Sodium (mmol/L)                     140.5±3.3             137.3±5.9                  139.2±4.7             \<0.001
   Haemoglobin (g/L)                   127.6±18.3            123.2±24.8                 125.9±21.2            0.019
  Outcomes                                                                                                    
   Peripheral oedema (n (%))           215 (58.0)            145 (59.2)                 338 (63.4)            0.004
   WRF (n (%))                         30 (8.1)              37 (20.7)                  67 (14.3)             \<0.001
   In-hospital mortality (n (%))       7 (1.9)               17 (8.2)                   24 (5.1)              \<0.001
   1-year mortality (n (%))            50 (17.2)             --                         --                    --
   Rehospitalisation (n (%))           188 (66.2)            --                         --                    --
   Length of hospital stay (days)      7 (4--9)              6 (3--8)                   6 (4--9)              0.320

Continuous data presented as mean±SD or median (Q1--Q3), depending on distribution.

ARB, angiotensin receptor blocker;BNP, B-type natriuretic peptide;CXR, chest X-ray;HARVEST, HeArt and bRain failure inVESTigation trial; NT-proBNP, N-terminal proBNP;bio-ADM, bioactive adrenomedullin; penKid, proenkephalin A 119--159.

Congestion {#s3-1}
----------

The ROC analyses for bio-ADM and peripheral oedema resulted in an AUC of 0.745 (95% CI 0.684 to 0.807) (HARVEST-Malmö), 0.651 (95% CI 0.576 to 0.726) (GREAT Network Rome) and 0.710 (95% CI 0.663 to 0.757) (pooled cohort). Logistic regression analyses carried out for bio-ADM and each sign of congestion (dyspnoea, oedema, signs of pulmonary oedema on chest X-ray and lung rales) revealed that each one SD increment of bio-ADM was significantly associated with peripheral oedema ([table 2](#T2){ref-type="table"}). The distribution of bio-ADM according to peripheral oedema for each centre is illustrated in [figure 1](#F1){ref-type="fig"}. Analyses of bio-ADM and severe congestion (congestions score of 4) revealed significant associations between each one SD increment of bio-ADM and risk of having the highest congestion score; however, those associations are driven mainly by the presented associations of bio-ADM and peripheral oedema ([table 2](#T2){ref-type="table"}). Subgroup analyses revealed that the association of bio-ADM and peripheral oedema was present and significant in both sexes when analysed separately (men: OR 2.46 (95% CI 1.63 to 3.69); p\<0.001 and women: OR 2.17 (95% CI 1.56 to 3.03); p\<0.001) in fully adjusted model.

###### 

Associations of bio-ADM and congestion

  Univariable model      HARVEST-Malmö   GREAT Network Rome    Pooled cohort                                                                               
  ---------------------- --------------- --------------------- --------------- ---------- --------------------- --------- ---------- --------------------- ---------
   Peripheral oedema     276; 200        2.93 (2.04 to 4.21)   \<0.001         192; 116   1.71 (1.24 to 2.36)   \<0.001   486; 322   2.22 (1.76 to 2.80)   \<0.001
   Persistent dyspnoea   295; 272        1.03 (0.67 to 0.58)   0.888           191; 177   0.76 (0.46 to 1.23)   0.302     486; 449   0.90 (0.64 to 1.24)   0.507
   Congestion on X-ray   274; 239        0.98 (0.69 to 1.39)   0.914           188; 169   1.11 (0.68 to 1.79)   0.677     462; 408   0.99 (0.75 to 1.33)   0.997
   Rales                 291; 209        0.96 (0.75 to 1.23)   0.746           192; 160   1.09 (0.74 to 1.61)   0.650     483; 364   0.93 (0.76 to 1.15)   0.498
   Severe congestion     253; 122        1.59 (1.22 to 2.06)   \<0.001         187; 76    1.30 (0.97 to 1.75)   0.077     440; 198   1.47 (1.21 to 1.78)   \<0.001
  Model 1                                                                                                                                                  
   Peripheral oedema     276; 200        3.12 (2.14 to 4.56)   \<0.001         192; 116   1.69 (1.22 to 2.35)   0.002     486; 322   2.29 (1.81 to 2.91)   \<0.001
   Persistent dyspnoea   295; 272        1.04 (0.68 to 1.59)   0.852           191; 177   0.72 (0.42 to 1.21)   0.213     486; 449   0.92 (0.66 to 1.29)   0.239
   Congestion on X-ray   274; 239        0.97 (0.68 to 1.38)   0.967           188; 169   1.12 (0.69 to 1.82)   0.653     462; 408   0.98 (0.73 to 1.29)   0.867
   Rales                 291; 209        0.96 (0.75 to 1.24)   0.780           192; 160   1.11 (0.75 to 1.64)   0.598     483; 364   0.96 (0.78 to 1.19)   0.722
   Severe congestion     253; 122        1.65 (1.26 to 2.17)   \<0.001         187; 76    1.27 (0.94 to 1.71)   0.115     440; 198   1.48 (1.21 to 1.80)   \<0.001
  Model 2                                                                                                                                                  
   Peripheral oedema     276; 200        3.01 (2.02 to 4.47)   \<0.001         192; 116   1.79 (1.26 to 2.54)   0.001     486; 322   2.30 (1.29 to 2.97)   \<0.001
   Persistent dyspnoea   295; 272        0.97 (0.61 to 1.55)   0.903           191; 177   0.79 (0.45 to 1.39)   0.451     486; 449   0.95 (0.66 to 1.36)   0.948
   Congestion on X-ray   274; 239        0.93 (0.65 to 1.34)   0.702           188; 169   0.99 (0.58 to 1.69)   0.973     462; 408   0.90 (0.67 to 1.22)   0.491
   Rales                 291; 209        0.94 (0.71 to 1.25)   0.680           192; 160   1.18 (0.78 to 1.80)   0.436     483; 364   0.98 (0.78 to 1.24)   0.884
   Severe congestion     253; 122        1.58 (1.18 to 2.11)   \<0.002         187; 76    1.33 (0.97 to 1.82)   0.079     440; 198   1.46 (1.18 to 1.80)   \<0.001

Values are OR with 95% CI for associations of bio-ADM and each sign of congestion, as well as bio-ADM and severe congestion (highest values on the congestion score (CCS=4). Model 1 is age and sex adjusted. Model 2 is further adjusted for systolic blood pressure, log-transformed and normalised B-type natriuretic peptide, prevalent atrial fibrillation and prior heart failure.

CCS, clinical congestion score; HARVEST, HeArt and bRain failure inVESTigation trial; bio-ADM, bioactive adrenomedullin.

![Distribution of bio-ADM according to signs of peripheral oedema within each centre. HARVEST-Malmö n=301, 215 events (p\<0.001), GREAT Network Rome n=208, 123 events (p=0.080). bio-ADM, bioactive adrenomedullin, HARVEST, HeArt and bRain failure inVESTigation trial.](openhrt-2019-001048f01){#F1}

Worsening renal function {#s3-2}
------------------------

Spearman correlation analyses for penKid and plasma creatinine at admission resulted in R of 0.577 (p\<0.001) (HARVEST-Malmö), 0.645 (p\<0.001) (GREAT Network Rome) and 0.598 (p\<0.001) (pooled cohort).

The ROC analyses for penKid and WRF resulted in an AUC of 0.654 (95% CI 0.552 to 0.757) (HARVEST-Malmö), 0.591 (95% CI 0.490 to 0.692) (GREAT Network Rome) and 0.652 (95% CI 0.583 to 0.721) (pooled cohort). In crude logistic regression models, and further adjusted for diabetes, SBP, ACEi, angiotensin receptor blockers (ARB), beta-blockers, prior heart failure, creatinine and BNP in the pooled cohort, penKid was associated with WRF ([table 3](#T3){ref-type="table"}). Further, we also analysed WRF using the delta creatinine (creatine after 48 hours---creatinine at admission) as a dependent variable in multivariate linear regression analyses, and the analyses revealed significant associations between penKid and delta creatinine (crude model (β −0.422; p=0.002); multivariate model adjusted for diabetes, SBP, ACEi, ARB, beta-blockers, prior heart failure, creatinine and BNP (β −0.392; p=0.004) in the pooled cohort. The distribution of penKid according to WRF for each centre is illustrated in [figure 2](#F2){ref-type="fig"}. Subgroup analyses revealed that the association of penKid and WRF was present and significant in men (OR 3.72 (95% CI 2.00 to 6.92); p\<0.001), but only a trend was seen in women (OR 1.42 (95% CI 0.98 to 2.05); p=0.063) in fully adjusted model.

###### 

Associations of penKid and worsening renal function

  Univariable           HARVEST-Malmö             GREAT Network Rome   Pooled cohort                                 
  -------------- ------ --------------- --------- -------------------- --------------- ------- ------ -------------- ---------
  Age            0.98   0.95 to 1.02    0.299     1.01                 0.97 to 1.04    0.715   1.00   0.98 to 1.03   0.932
  Sex            6.72   1.57 to 28.8    0.010     0.94                 0.48 to 1.84    0.847   1.22   0.73 to 2.04   0.443
  Diabetes       1.40   0.65 to 3.03    0.389     1.12                 0.56 to 2.2     0.751   1.23   0.74 to 2.04   0.425
  SBP            1.00   0.98 to 1.01    0.621     1.01                 1.00 to 1.02    0.158   1.01   1.00 to 1.02   0.100
  ACE-i          0.72   0.34 to 1.52    0.384     1.32                 0.66 to 2.64    0.432   0.83   0.51 to 1.37   0.468
  ARB            0.60   0.22 to 1.64    0.320     0.52                 0.21 to 1.31    0.165   0.54   0.28 to 1.06   0.074
  Betablockers   1.32   0.38 to 4.56    0.665     1.20                 0.61 to 2.36    0.590   0.81   0.47 to 1.39   0.444
  Prior HF       1.14   0.84 to 1.55    0.407     0.71                 0.35 to 1.42    0.330   0.90   0.62 to 1.31   0.590
  Creatinine     2.73   1.79 to 4.18    \<0.001   1.16                 0.83 to 1.62    0.396   1.63   1.28 to 2.08   \<0.001
  BNP            1.16   0.79 to 1.70    0.459     0.90                 0.64 to 1.26    0.532   1.01   0.78 to 1.29   0.966
  PenKid         1.81   1.21 to 2.70    0.004     1.37                 0.99 to 1.89    0.059   1.67   1.31 to 2.14   \<0.001

  Multivariable                                           
  --------------- -- -- -- -- -- -- ------ -------------- -------
  Age                               0.98   0.95 to 1.01   0.173
  Sex                               1.54   0.80 to 2.98   0.197
  Diabetes                          0.92   0.51 to 1.66   0.919
  SBP                               1.00   0.99 to 1.01   0.373
  ACEi                              0.80   0.43 to 1.50   0.483
  ARB                               0.47   0.21 to 1.04   0.063
  BB                                0.98   0.50 to 1.91   0.946
  Prior HF                          1.02   0.72 to 1.43   0.926
  BNP                               0.78   0.57 to 1.06   0.115
  Creatinine                        1.68   0.69 to 4.05   0.251
  PenKid                            1.74   1.20 to 2.53   0.004

Values are OR with 95% CI. Multivariable results are reported for the pooled cohort adjusted for variables known from literature.

ACE-I, ACE inhibitors;ARB, angiotensin receptor blocker;BNP, B-type natriuretic peptide;HARVEST, HeArt and bRain failure inVESTigation trial; HF, heart failure; SBP, systolic blood pressure; penKid, proenkephalin A 119--159.

![Distribution of penKid according to worsening renal function in each centre. HARVEST-Malmö n=323, 30 events (p=0.003), GREAT Network Rome n=178, 37 events (p=0.050). PenKid, proenkephalin A 119--159HARVEST, HeArt and bRain failure inVESTigation trial.](openhrt-2019-001048f02){#F2}

In-hospital mortality {#s3-3}
---------------------

### Bioactive adrenomedullin {#s3-3-1}

Univariable and bivariable logistic regression models exploring associations of bio-ADM with in-hospital mortality are presented in [table 4](#T4){ref-type="table"} (n=470; 24 events). As for ROC analyses, the AUC for bio-ADM and in-hospital mortality was 0.614 (95% CI 0.467 to 0.761) (HARVEST-Malmö), 0.657 (95% CI 0.507 to 0.807) (GREAT Network Rome) and 0.606 (95% CI 0.483 to 0.729) (pooled cohort). Subgroup analyses revealed that the association of bio-ADM and in-hospital mortality was present and significant in men (OR 1.76 (95% CI 1.04 to 2.97); p=0.034), but not in women (OR 1.33 (95% CI 0.69 to 2.56); p=0.394). However, due to the low number of events when analysed separately, those results should be interpreted with caution.

###### 

Logistic regression model for in-hospital mortality for bio-ADM and penKid

                 Univariable   Bivariable: BioADM   Bivariable: PenKid                                                       
  -------------- ------------- -------------------- -------------------- ------ -------------- ------- ------ -------------- ---------
  Age            1.04          0.99 to 1.09         0.067                1.54   1.03 to 2.31   0.037   2.16   1.49 to 3.13   \<0.001
  Sex            0.53          0.24 to 1.16         0.112                1.58   1.05 to 2.37   0.028   2.19   1.53 to 3.14   \<0.001
  Diabetes       0.85          0.37 to 1.92         0.689                1.52   1.01 to 2.28   0.045   2.23   1.56 to 3.19   \<0.001
  SBP            0.99          0.98 to 1.01         0.254                1.48   0.98 to 2.25   0.063   2.28   1.59 to 3.27   \<0.001
  ACE-i          0.60          0.26 to 1.36         0.217                1.49   0.99 to 2.23   0.056   2.24   1.56 to 3.21   \<0.001
  ARB            0.92          0.46 to 1.81         0.798                1.51   1.01 to 2.27   0.049   2.27   1.58 to 3.25   \<0.001
  Betablockers   0.20          0.09 to 0.46         \<0.001              1.61   1.08 to 2.40   0.020   2.08   1.44 to 3.00   \<0.001
  Prior HF       0.54          0.25 to 1.19         0.127                1.63   1.09 to 2.46   0.018   2.22   1.56 to 3.15   \<0.001
  Creatinine     1.77          1.27 to 2.46         0.001                1.38   0.90 to 2.11   0.139   2.31   1.51 to 3.53   \<0.001
  BNP            1.28          0.85 to 1.92         0.235                1.42   0.93 to 2.15   0.105   2.29   1.56 to 3.35   \<0.001
  Smoking        0.43          0.10 to 1.84         0.255                1.47   0.97 to 2.21   0.067   2.25   1.57 to 3.23   \<0.001
  Prevalent AF   0.47          0.20 to 1.09         0.078                1.50   1.01 to 2.25   0.047   2.18   1.53 to 3.11   \<0.001
  Bio-ADM        1.50          1.00 to 2.26         0.051                                              2.19   1.52 to 3.15   \<0.001
  penKid         2.24          1.57 to 3.20         \<0.001              1.34   0.88 to 2.03   0.168                         

Values are OR with 95% CI. All results are reported for the pooled cohort (n=470, 24 events). Univariable results are presented as each variable's associations with in-hospital mortality. Bivariable results are reported for penKid and bio-ADM, adjusted for each variable separately.

ACE-I, ACE inhibitors; AF, atrial fibrillation; ARB, angiotensin receptor blocker; BNP, B-type natriuretic peptide; Bio-ADM, bioactive adrenomedullin; HF, heart failure; SBP, systolic blood pressure; penKid, proenkephalin A 119--159.

### Proenkephalin {#s3-3-2}

Univariable and bivariable logistic regression models exploring associations of penKid with in-hospital mortality are presented in [table 4](#T4){ref-type="table"}, where penKid was associated with in-hospital mortality in all analyses. The ROC analyses for penKid and in-hospital mortality resulted in an AUC of 0.630 (95% CI 0.396 to 0.864) (HARVEST), 0.732 (95% CI 0.596 to 0.868) (GREAT Network Rome) and 0.735 (95% CI 0.618 to 0.851) (pooled cohort). Subgroup analyses revealed that the association of penKid and in-hospital mortality was present and significant in both sexes when analysed separately (women: OR 1.78 (95% CI 1.06 to 3.00); p=0.029 and men: OR 2.71 (95% CI 1.59 to 4.62); p\<0.001).

One-year mortality {#s3-4}
------------------

Due to the low event rate for in-hospital mortality in HARVEST-Malmö, we performed additional analyses of biomarkers and 1-year mortality (n=290, 50 events).

### Bioactive adrenomedullin {#s3-4-1}

ROC analyses of bio-ADM for 1-year mortality resulted in an AUC of 0.586 (95% CI 0.502 to 0.669), p=0.044. Cox regression models revealed that each one SD increment in bio-ADM was associated with increased 1-year mortality in the crude model (HR 1.38, 95% CI 1.03 to 1.74, p=0.029), age-adjusted and sex-adjusted model (HR 1.33, 95% CI 1.03 to 1.72, p=0.029) and further adjusted for diabetes, SBP, atrial fibrillation, smoking, NT-proBNP and prior heart failure (HR 1.35, 95% CI 1.01 to 1.79, p=0.043).

### Proenkephalin {#s3-4-2}

ROC analyses of penKid and 1-year mortality resulted in an AUC of 0.639 (95% CI 0.549 to 0.729), p=0.001. Cox regression models revealed that each one SD increment in penKid levels was associated with increased 1-year mortality in crude analyses (HR 1.66, 95% CI 1.31 to 2.10, p\<0.001), in an age-adjusted and sex-adjusted model (HR 1.49, 95% CI 1.14 to 1.94, p=0.004) and further adjusted for diabetes, SBP, atrial fibrillation, smoking, NT-proBNP and prior heart failure (HR 1.35, 95% CI 1.04 to 1.77, p=0.027).

Rehospitalisation {#s3-5}
-----------------

### Bioactive adrenomedullin {#s3-5-1}

ROC analyses of bio-ADM and rehospitalisation resulted in AUC of 0.585 (95% CI 0.517 to 0.654), p=0.017. Analyses of bio-ADM and risk of rehospitalisation (n=284; 188 events; mean follow-up time 174 days) were carried out in a crude model (HR 1.19, 95% CI 1.05 to 1.36, p=0.008), age-adjusted and sex-adjusted model (HR 1.19, 95% CI 1.05 to 1.36, p=0.008) and further adjusted for diabetes, SBP, atrial fibrillation, smoking, log-transformed and z-normalised BNP and prior heart failure (HR 1.15, 95% CI 1.06 to 1.47, p=0.007) and revealed that each one SD increment of bio-ADM was associated with increased risk of rehospitalisation.

### Proenkephalin {#s3-5-2}

Analyses of penKid and risk of rehospitalisation revealed that there were no significant associations (data not shown).

Length of hospital stay {#s3-6}
-----------------------

### Bioactive adrenomedullin {#s3-6-1}

In linear regression analyses in the pooled cohort, each one SD increment of bio-ADM was associated with longer hospital stay on admission in crude analysis (β 0.700; p=0.004), in age-adjusted and sex-adjusted analysis (β 0.709; p=0.003), and remained so after further adjustment for diabetes, SBP, prevalent atrial fibrillation, smoking and prior heart failure (β 0.702; p=0.005).

### Proenkephalin {#s3-6-2}

In linear regression analyses, no significant associations were seen for penKid and length of hospital stay (data not shown).

Discussion {#s4}
==========

In this observational study of two AHF cohorts, we could show that bio-ADM was a suitable biomarker for early detection and quantification of congestion severity (mainly driven by peripheral oedema), risk of rehospitalisation and longer hospital stay, while penKid was a suitable biomarker in detection of WRF occurrence and both in-hospital and 1-year mortality. This is, to our knowledge, the first time that data regarding penKid and bio-ADM are presented when used simultaneously in patients with AHF in two independent cohorts. These data imply that in an everyday clinical setting, bio-ADM and penKid could be useful to guide diuretic therapy. Since increased bio-ADM is associated with clinical congestion, this might be used to identify individuals with the need of intensified diuretic therapy. As treatment of AHF and decongestion might be harmful to the kidneys, the combination of the two biomarkers appears advantageous, where penKid can aid in guiding the treatment so not to jeopardise renal function ([figure 3](#F3){ref-type="fig"}).

![The clinical use of Bioactive adrenomedullin (bio-ADM) and proenkephalin A 119--159 (penKid) for management of heart failure.](openhrt-2019-001048f03){#F3}

Bioactive adrenomedullin {#s4-1}
------------------------

Bio-ADM is known as a vasodilation factor,[@R18] and the prognostic value of bio-ADM has been shown in several different critical conditions.[@R8] Moreover, its predictive role was recently extended to the AHF setting. Self *et al* showed that in patients with AHF, higher bio-ADM levels were associated with the composite primary outcome consisting of death, rehospitalisation, emergency dialysis, cardiac arrest with resuscitation, respiratory failure, prolonged hospitalisation and acute coronary syndrome within 30 days.[@R10] Furthermore, they suggested that bio-ADM provides predictive information independent of more established biomarkers in AHF such as natriuretic peptides and troponins. This view is supported by our findings where bio-ADM predicted 1-year mortality and in-hospital mortality. The confirmation of congestion by laboratory results is, at present, challenging, and the evaluation of bio-ADM might provide a new opportunity to guide clinical decisions. In this context, our findings showing high levels of bio-ADM to be associated with increased length of hospital stay and increased risk of rehospitalisation are of great interest, suggesting bio-ADM as a possible new tool to pinpoint which patients could benefit from a more active treatment in order to reduce length of stay and risk of readmission. This reasoning is further supported by a recent study by Kremer *et al*[@R9] that showed a significant decrease in bio-ADM for admitted patients with AHF with little or no residual congestion after 1 week, compared with patients with significant residual congestion. Further, bio-ADM was the strongest predictor of prevalent congestion among 13 covariates.[@R9] Recently, a promising drug candidate (adrecizumab) targeting bio-ADM has been developed.[@R21]

Proenkephalin {#s4-2}
-------------

PenKid is considered an inflammation-independent marker of kidney function that allows the early diagnosis of acute kidney injury by predicting the future change in serum creatinine.[@R23] Its highly dynamic nature enables close monitoring of renal function. In our study, penKid correlated with serum creatinine levels. In addition, penKid was associated with WRF and both in-hospital and 1-year mortality. These results are in line with Ng *et al*'s study in the AHF setting,[@R15] as well as in the stable heart failure setting.[@R24]

The pathophysiological mechanism suggested for penKid, both in WRF and its prognostic value in mortality, might be related to cardiodepressive effects of enkephalins[@R11] which would cause reduced kidney perfusion and advancing heart failure. This theory is supported by the results from the Acute Decompensated Heart Failure National Registry where administration of opiates resulted in worse prognosis in heart failure.[@R25]

Even if bio-ADM and penKid most likely reflect different pathophysiological mechanisms (ie, bio-ADM and congestion, penKid and WRF), the combination of the two could yield complementary information regarding the cardiorenal syndrome in patients with AHF. Further prospective studies are indeed warranted.

Study limitations {#s4-3}
-----------------

An important strength of the current study is the use of two well-characterised prospective AHF cohorts. There are, however, several limitations with this study. The two cohorts, while fairly comparable in age and have a medical history, differ significantly in use of medications as well as mortality rate with a lower event rate in the HARVEST cohort. This is most likely due to the fact that patients in the HARVEST cohort were recruited from the wards, while the patients in the GREAT Network Rome cohort were recruited directly from the emergency department. Consequently, treatment for AHF (ie, diuretics) was already initiated in most patients in the HARVEST cohort. The low-event rate is also most likely an effect of this as the most severe cases of AHF with the worst prognosis would be treated in the intensive care unit or the cardiac intensive care unit and not in one of the participating recruiting wards in the HARVEST cohort. The aetiology of heart failure was not registered. Data on signs of congestion, which was the basis for our congestion score, were not collected per protocol prospectively, but gathered retrospectively from the admittance record and thus subjected to the admitting doctor's precision and record-keeping. This could explain the lack of significance for the congestive signs other than peripheral oedema, as they presumably are more subjective and more prone to include conditions other than congestion. Data on congestion at discharge was not available, and we acknowledge that assessment of residual congestion at discharge would have added value to the study, especially paired with serial measurements of bio-ADM and penKid. Finally, the study was undertaken in individuals of mainly European descent, and the conclusions may not be generalisable to all ancestries.

Conclusion {#s5}
==========

In two separate AHF cohorts, bio-ADM and penKid perform as suitable biomarkers for early detection of congestion severity and WRF occurrence, respectively, and are both associated with adverse clinical outcomes. The simultaneous evaluation of the two biomarkers in patients with AHF could provide important information in therapeutic decision-making in order to reduce patient's mortality, in-hospital length of stay and rehospitalisation rate. Further prospective studies are needed to confirm this hypothesis.
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